Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

t an expanded cohort of patients at the maximum tolerated dose.  The company has cleared a safety review after dosing the 5 mg/kg cohort and has authorization to start enrolling patients at 10 mg/kg.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673.  In the first quarter of 2011, the company initiated a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors.  In July 2011, the company initiated a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  The primary objective of the studies is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.  

  • Preclinical Programs

  • BMN-111 for Achondroplasia: Regulatory interactions are underway, and BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth, for achondroplasia, the most common form of dwarfism.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and six months ended June 30, 2011 and June 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... July 10, 2014 Decision Resources Group finds ... the U.S. Food and Drug Administration,s (FDA) approval of ... Velphoro, which was approved by the FDA in November ... disease (CKD) patients on dialysis. Other key ... (US) Q2 2014 : ...
    (Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
    (Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
    Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
    ... The End of Polio Concert, funded by the ... 2011, in Perth Australia, has resulted in an unprecedented ... The highly publicized and critically acclaimed concert, which ... Polio Eradication Initiative, has resulted in contributions of $50 ...
    ... Conn., Nov. 7, 2011 Planet Biopharmaceuticals, Inc. and ... specialty pharmaceutical company focused on providing products for allergy ... an asset sale of ALLERGY CONTROL PRODUCTS, INC., a ... Jersey limited liability company. Theron E. Odlaug, ...
    Cached Medicine Technology:Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 2Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 3Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio 4
    (Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
    (Date:7/13/2014)... July 13, 2014 The federal court ... ) filed against Johnson & Johnson’s Ethicon, Inc. ... which is expected to get underway next month. According ... U.S. District Court, Southern District of West Virginia on ... on August 7, 2014 at 3:00 p.m. July selection ...
    (Date:7/13/2014)... Max International has recently ... be the featured guest at its Charity Exhibition and ... Attendees will learn about Max’s health products and ... basketball games and perform in a 3 point shoot-out. ... and energy-boosting supplements , has recently announced former NBA ...
    (Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace ... Recently, the company has announced its new selection of ... all these outfits are available at discounted prices (from ... supplier is now offering similar discounts for many other ... many other designs for sale, including flower girl dresses, ...
    (Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
    Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
    ... -- Most children born with HIV infection now survive ... death that awaited HIV-infected babies years ago, researchers report. ... AIDS-causing virus, to better understand the effects of treatment ... these kids, at this point, don,t have virus detectable ...
    ... Associations for Dental Research (IADR/AADR) have published two studies ... income individuals. These articles, titled "Income-related Inequalities in Dental ... and "Income Inequality and Tooth Loss in the United ... in the Journal of Dental Research, the official publication ...
    ... By Dennis Thompson HealthDay Reporter , ... and the American Heart Association have put forth an ... attack, stroke and coronary heart disease. The goals ... and illness, however. They place even greater emphasis on ...
    ... Columbia Business School is proud to announce that Frank ... Finance and Economics and the Healthcare and Pharmaceutical Management ... by the Emerald Literati Network. The award recognizes an ... book series published by Emerald Group Publishing, a leading ...
    ... , FRIDAY, April 22 (HealthDay News) -- Lynne Braun spends a ... by their hearts and their health. Braun, who works as ... teaches at the university,s College of Nursing, helps counsel people who ... who,ve had a heart attack or stroke and hope to ...
    ... Healthcare today teleconferenced one of the world,s first live ... to conference attendees in Sao Paolo, Brazil. The meeting, ... of the globe,s largest vascular surgery events and includes ... an endograft device called a repositionable endoprosthesis. ...
    Cached Medicine News:Health News:HIV Kids Growing Up Well, Study Finds 2Health News:IADR/AADR Journal of Dental Research releases studies on oral health inequalities in older people 2Health News:To Get Americans Healthier, U.S. Targets the Heart 2Health News:To Get Americans Healthier, U.S. Targets the Heart 3Health News:To Get Americans Healthier, U.S. Targets the Heart 4Health News:Columbia business school’s Frank Lichtenberg awarded by the Emerald Literati Network 2Health News:Nurse Practitioner Counsels Lifestyle Changes as Key to Heart Health 2Health News:Nurse Practitioner Counsels Lifestyle Changes as Key to Heart Health 3Health News:Scott & White Healthcare broadcasts live surgery to São Paolo, Brazil 2
    ... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
    St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
    The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
    ... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
    Medicine Products: